Objectives: To assess the in vitro antibiotic susceptibility of Enterococcus faecalis in biofilms.
Introduction
Orthopaedic prosthetic devices are increasingly used in humans due to a growing elderly population and more-advanced implant technology. 1 In most cases the devices offer regained structure and function, but sometimes implant-associated infections develop. 2, 3 Such infections are feared complications causing significant morbidity and they are a profound economic burden for society. 4, 5 In infections related to implanted devices, bacteria typically form biofilms on the foreign material, making the infections difficult to treat. A biofilm is a structured community of microorganisms adhering to a surface and encapsulated within a self-produced highly-hydrated extracellular matrix. 6, 7 Bacterial biofilms exhibit recalcitrance to antimicrobial compounds and resist the action of human immune defences. 8 -14 Cure of prosthetic joint infections (PJIs) where bacteria form biofilm is in most cases dependent on surgical removal of the foreign material, or on prolonged treatments, often employing more than one antibiotic. 15, 16 Staphylococcus aureus and coagulase-negative staphylococci are the major pathogens responsible for implantassociated infections, and conventional antibiotic therapy has a high rate of failure. 17 Experimental and clinical studies conducted in the early 1990s showed that regimens with rifampicin in combination with fluoroquinolones could eradicate staphylococcal biofilms and cure implant-associated infections. 18 -21 A concern with using rifampicin is that rapid development of resistance may occur. It has previously been shown that development of resistance is limited by combining rifampicin with a fluoroquinolone or with linezolid. 22, 23 Enterococci have become increasingly recognized as important pathogens causing infections associated with medical devices. 3, 15, 24 Treatment of Enterococcus faecalis infections is complicated both by the antimicrobial resistance of the bacterium and by the ability of the bacterium to form biofilm. 14, 25 The effect of conventional antibiotics such as b-lactams or aminoglycosides on E. faecalis in biofilm or in PJI has not been thoroughly studied. Resistance to aminoglycosides among E. faecalis isolates is increasing, and b-lactams are regarded as ineffective against bacteria in stationary phase or in biofilm. This gives us few options for rational treatment of PJI with E. faecalis, and there is a need for novel treatment strategies for E. faecalis in biofilms. 24, 26 In this study we evaluated the activity of ciprofloxacin, ampicillin, vancomycin and linezolid, alone and in combination with rifampicin, against biofilms of four E. faecalis isolates from PJIs.
Materials and methods

Isolates and culture conditions
Fifteen clinical isolates of E. faecalis were collected from the accredited diagnostic laboratory for Clinical Microbiology, Skå ne University Hospital, Lund, Sweden. All isolates originated from tissue adjacent to infected prosthetic hip and knee joints. The isolates were from one of multiple positive cultures from the same patients. E. faecalis was identified based on typical colony morphology, the ability to convert tellurite to tellurium, a typical antibiotic susceptibility pattern, catalase negativity and the ability to utilize pyruvate. The bacteria were cultivated in tryptic soy broth (Becton and Dickinson, Sparks, MD, USA) supplemented with 0.5% glucose (TSBG) at 378C with 5% CO 2 for 16-18 h. For determination of cfu, bacteria were serially diluted in sterile PBS, plated onto TSBG agar and incubated as above. Colonies were counted manually. All experiments were performed three times.
Cement beads
Cement beads were prepared under sterile conditions. Antibiotic-free bone cement (Biomet Cementing Technologies AB, Sjö bo, Sweden) was mixed in Optivac (Biomet) under vacuum for 30 s. The mixture was injected into a mould with 100 holes with a diameter of 6 mm and a thickness of 3 mm. The mould was compressed under 2.5 tons until the cement was set.
Antibiotics
Ampicillin, as a sodium salt, was from Sigma-Aldrich Chemie (Steinheim, Germany), ciprofloxacin (Ciproxin infusion, 2000 mg/L) was from Bayer Health Care AG (Leverkusen, Germany), rifampicin powder (Rifadin) was from Aventis Pharma AB (Stockholm, Sweden), linezolid (Zyvoxid infusion 2000 mg/L) was from Pfizer AB (Sollentuna, Sweden) and vancomycin was from Nordmedica A/S (Copenhagen, Denmark). Powdered antibiotics were dissolved in sterile nanopure water to a concentration of 10000 mg/L and were freshly made for each experiment. Etests were from bioMérieux (Solna, Sweden).
MIC and minimal biofilm eradication concentration (MBEC)
MIC was determined by adding bacteria to saline to correspond to the 0.5 McFarland standard followed by plating on a NAD-resistance plate (Iso-Sensitest agar with NAD, supplemented with 5% defibrinated horse blood; Duchefa Biochemie BV, Haarlem, The Netherlands). The Etest was applied and MIC was defined as the point of intersection between bacterial growth and the Etest.
MBEC was determined by a modification of the Calgary Biofilm Device method. 27 Bacterial suspension (18 mL) from an overnight culture was added to 162 mL of TSBG in the wells of a microtitre plate followed by the application of a lid with 96 pegs (MBEC TM Physiology & Genetics assay; Innovotech Inc., Edmonton, Alberta, Canada). Biofilm was allowed to form on the pegs of the lid for 24 h for the MBEC TM P&G assay. The lid was then transferred to a standard 96-well plate (Nunclon surface; Nunc A/S, Roskilde, Denmark) in which each well contained 200 mL of TSBG and antibiotics in concentrations ranging from 1024 to 1 mg/L in 2-fold dilutions. When combining antibiotics, rifampicin was used in a concentration of 8 mg/L. For each isolate, one well contained just medium (negative control) and one well contained medium and bacteria but no antibiotics (positive control). Pegs were incubated with antibiotics for 8 h, after which the lid was removed and washed once by immersion in a microtitre plate containing 200 mL of sterile PBS in each well. The lid was then placed in a new microtitre plate containing 200 mL TSBG and put in an XB2 ultrasonic bath (Grant Instruments, Cambridge, UK) for 5 min. The lid with pegs was removed and a new plate cover (devoid of pegs) was applied and the plate was incubated overnight. The MBEC was determined as the lowest concentration of the respective antibiotic able to suppress visible growth of the bacteria in the microtitre plate wells. The biofilmfree pegs never produced growth and the wells with pegs not treated with antibiotics were always turbid.
Time -kill assay
Bacterial biofilm was established in microtitre plate wells (Nunclon Surface F, Nunc A/S) by the addition of 18 mL of bacterial overnight culture to 162 mL of TSBG and incubation for 24 h at 378C. After removal of medium and washing once with sterile TSBG, 200 mL of TSBG containing 8 mg/L of antibiotics, either alone or in combination with 8 mg/L of rifampicin, was added. After incubation at 378C in 5% CO 2 for 2, 8 and 24 h, the wells were emptied and the biofilm was gently washed twice with 200 mL of PBS. PBS (200 mL) was added to each well and the biofilm was removed from the wells by scraping with a plastic pipette tip. The scraping procedure was repeated once and the 400 mL of PBS containing the bacteria was diluted to 1 mL in an Eppendorf tube. The tube was vortexed at high speed for 30 s followed by ultrasonication for 5 min (XB2, Grant Instruments). After serial dilutions, the number of cfus was determined. Biofilm was established on cement beads by adding one bead to 900 mL of TSBG in an Eppendorf tube. Bacterial overnight culture (100 mL) was added and the mixture was incubated for 24 h. The Eppendorf tubes were emptied and TSBG with 8 mg/L of antibiotics, either alone or in combination with 8 mg/L rifampicin, were added. After incubation at 378C in 5% CO 2 for 8 h, the Eppendorf tubes were emptied and the cement bead was gently washed with 200 mL of PBS twice. One mL of PBS was added to each Eppendorf tube with the cement bead and vortexed for 1 min at high speed followed by ultrasonication (Hielscher Ultrasonics GmbH, Teltow, Germany) for 15 s twice (amplitude: 100%, sonic: 0.5). After serial dilutions, the suspension was plated and cultured overnight.
Statistics
Statistical analyses were performed using GraphPad Prism, version 5.03 for Windows (GraphPad Software, San Diego, CA, USA).
Electron microscopy
For scanning electron microscopy (SEM), bacterial biofilm adsorbed to bone cement beads was fixed in formaldehyde/glutaraldehyde (4%/2.5%) in PBS for 2 h at 48C. Fixed specimens were dehydrated for 10 min at each step of an ascending ethanol series, and critical point dried in a Balzers critical point dryer in liquid CO 2 , using absolute ethanol as the intermediate solvent. Samples were examined under a Jeol J-330 scanning electron microscope with an acceleration voltage of 5 kV and a working distance of 10 mm.
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Results
MIC and MBEC determination
We analysed the susceptibility of 15 E. faecalis isolates derived from knee or hip prosthesis infections to ampicillin, vancomycin, ciprofloxacin, linezolid and rifampicin using Etests. All these antibiotics potentially have an effect on E. faecalis and they penetrate into bone tissue and articular joint fluid. Eleven isolates were susceptible to all antibiotics tested, whereas three isolates had MIC .16 mg/L for ciprofloxacin and one isolate had MIC 8 mg/L for rifampicin (Table 1) .
Next, we determined MBECs for various antibiotics in biofilms formed on plastic pegs of four isolates, all of which produced a biofilm in a classical microtitre-plate-based assay. 28 The (Table 1) . When combined with 8 mg/L rifampicin, MBECs for ciprofloxacin and linezolid dropped to 16 -32 mg/L, whereas MBECs for vancomycin and ampicillin were less affected by the addition of rifampicin ( Table 1) . The values given are the modes of MBEC. The majority of MBEC values were the same throughout all three experiments for each strain and antibiotic.
Time -kill of E. faecalis in biofilm on polystyrene plastic E. faecalis isolate ed9 was allowed to form biofilms in a 96-well polystyrene plate for 24 h. After washing, bacteria were exposed to different antibiotics at a concentration of 8 mg/L for 2, 8 and 24 h. For the antibiotics used, peak serum concentrations of 8 mg/L are attainable. 29 -33 After mechanical disruption of the biofilm, the number of cfus was determined. Bacterial killing by antibiotics was most prominent after 8 h (Figure 1 ). The number of cfus decreased to one-tenth in the control biofilm (not treated with antibiotics) between 8 and 24 h of incubation.
Biofilms of four isolates formed in the polystyrene 96-well plate were next subjected to time-kill experiments using 8 mg/L antibiotics for 8 h. For all isolates, the combination of ciprofloxacin and rifampicin was the most potent in reducing the number of cfus, followed by linezolid and rifampicin ( Figure 2 ).
Examination by SEM of biofilms formed on bone cement beads
To better reflect the situation in a PJI, we established biofilms on beads of bone cement. Using SEM we visualized a bead without bacteria ( Figure 3a ) and a bead with bacteria displaying an amorphous biofilm (Figure 3b ). After vortexing and sonication large parts of the biofilm had become solubilized (Figure 3c) .
Beads of bone cement with biofilm of E. faecalis isolate ed9 were exposed to antibiotics at a concentration of 8 mg/L for 8 h. As found for biofilm grown on polystyrene, the combination of rifampicin and ciprofloxacin, followed by rifampicin in combination with linezolid, yielded the greatest reduction in cfus ( Figure 4) . Beads with biofilm treated with antibiotics were also Antibiotics against E. faecalis in biofilms 435 JAC subjected to SEM examination; these demonstrated a disrupted biofilm architecture, especially when the biofilm had been treated with a combination of antibiotics (Figure 5a -c) .
Development of resistance to rifampicin
Biofilm was established on bone cement beads and exposed to rifampicin alone or in combination with ampicillin, linezolid or ciprofloxacin. The biofilm was exposed to antibiotics (all at 2 mg/L) for 16 h, followed by 8 h of incubation in antibiotic-free TSBG. This cycle was repeated three times-a total of 72 h. Bacteria were scraped off with a pipette and plated on TSBG agar, and on TSBG agar supplemented with rifampicin (4 mg/L). The number of cfus on the antibiotic-free plates was determined and a 0.5 -3 log reduction was observed. Ciprofloxacin or linezolid in combination with rifampicin was more potent in reducing bacterial number than the combination of ampicillin and rifampicin (Table 2) . Bacterial colonies growing on rifampicin-containing plates were quantified and significant bacterial growth was observed for biofilms that had been subjected to rifampicin, either alone or in combination with ampicillin. All these isolates also grew on plates with 32 mg/L rifampicin, indicating a high level of Surviving bacteria (cfu) in biofilm of E. faecalis isolate ed4, ed9, ed10 and ed12 on a plastic surface exposed to combinations of antibiotics during 8 h (see Figure 1 for abbreviations). Each bar represents the ratio between cfus in biofilm exposed to antibiotics alone and in combination with rifampicin, and the cfus in biofilm not exposed to antibiotics. Values are medians and error bars represent the range (n¼3). Figure 4 . Beads of bone cement with biofilm of E. faecalis isolate ed9 were exposed to antibiotics at a concentration of 8 mg/L, alone and in combinations, for 8 h. Bars represent ratio between cfus in biofilm on cement beads exposed to antibiotics and cfus in biofilm not exposed to antibiotics (see legend to Figure 1 for abbreviations) . rifampicin resistance. We also observed resistance to rifampicin, though to a much lower degree, when bacteria were subjected to a combination of ciprofloxacin and rifampicin or to a combination of linezolid and rifampicin (Table 2 ). Importantly none of the rifampicin-resistant bacteria showed increased MICs of ciprofloxacin. Biofilm on cement beads in only TSBG for 72 h were used as control, and from these biofilms no bacteria yielded growth on plates supplemented with 4 mg/L rifampicin.
Discussion
E. faecalis is an emerging pathogen in hospital settings giving rise to a variety of invasive infections, including orthopaedic and foreign-body-related infections. 25, 34 There is an urgent need for new treatment strategies since E. faecalis has a pronounced antibiotic resistance and can form biofilm on foreign materials. 11, 14, 35 Inspired by work on S. aureus biofilms and PJI, we investigated the effects of rifampicin in combination with other antibiotics on E. faecalis biofilms formed in vitro. This work shows that ciprofloxacin combined with rifampicin, or linezolid combined with rifampicin, could be considered for treatment of infections where E. faecalis forms biofilm.
We studied the effects of different antibiotics on E. faecalis biofilms formed on plastic surfaces and determined the MBECs as well as the bactericidal effects of antibiotics at more physiological concentrations. The MBEC determination uses a higher concentration than is physiologically adequate, and thus always needs to be followed by time -kill experiments. The results from the two assays corresponded, thus showing that MBEC determination, which allows for investigation of many compounds and isolates, may be useful as a screening procedure. For selected isolates and antibiotics we also performed time -kill experiments on E. faecalis in biofilms formed on bone cement, which is a clinically relevant substrate. We chose to use a concentration of 8 mg/L, which is easily achievable for ampicillin, vancomycin and linezolid. 29 -31 Eight mg/L is somewhat higher than the median concentration achieved with ciprofloxacin and rifampicin 32, 33 with normal dosing so we also investigated the effect of prolonged exposure to 2 mg/L ciprofloxacin, linezolid, rifampicin and ampicillin on E. faecalis biofilms. In all these systems combinations between rifampicin and either ciprofloxacin or linezolid were more efficient than rifampicin with ampicillin or vancomycin. It should however be noted that no antibiotic was able to eradicate the biofilm even though the biofilm was established for only 24 h. It will be interesting to determine how antibiotics affect more mature E. faecalis biofilms and also how longer times of antibiotic exposure will affect the E. faecalis biofilm.
Rapid development of resistance both in vivo and in vitro to rifampicin, when used as monotherapy, has previously been described for many different bacterial species including S. aureus. 36 -38 In our system, rifampicin resistance developed in 72 h when rifampicin was used alone or in combination with ampicillin. When rifampicin was combined with ciprofloxacin or linezolid, resistance to rifampicin was also noted, though to a much lower degree. No ciprofloxacin resistance was detected throughout the course of the experiment. If rifampicin is considered for PJI with E. faecalis we believe that it should always be combined with either a fluoroquinolone or linezolid. We chose to study ciprofloxacin as the fluoroquinolone since this drug is well established for the treatment of PJI with S. aureus. A fluoroquinolone with a more Gram-positive spectrum, such as moxifloxacin, would also be interesting to test in our systems. In our tests, 3 out of 15 E. faecalis isolates were resistant to ciprofloxacin, and for those infections quinolones are not an option. The prevalence of fluoroquinolone resistance in E. faecalis has not been thoroughly studied, but resistance could limit the use of this combination in some countries. Resistance to linezolid in E. faecalis has so far only been described for a small number of isolates. 39, 40 To reduce the risk of the development of resistance to rifampicin, the number of bacteria in the planktonic phase and perhaps also in the biofilm could be lowered by an initial short course of b-lactam therapy followed by one of Antibiotics against E. faecalis in biofilms the rifampicin combinations. The rifampicin and ciprofloxacin combination is used for early PJI with S. aureus and is generally well tolerated. Longer treatments with linezolid will perhaps be less well tolerated due to the side effects of this antibiotic. Though much work remains, we believe that antibiotic treatments that include rifampicin for infections where E. faecalis forms biofilm should be tried, both in animal models and in humans. However, the risk of rapid development of resistance to rifampicin must always be considered.
